$MIRA

MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours - Mira Pharmaceuticals (NASDAQ:MIRA)

MIRA Pharmaceuticals, Inc. MIRA shares soared to $1.87, an approximate 50.8% jump, during after-hours trading on Wednesday. What Happened: After the announcement of Mira-55, a synthetic analog of marijuana, providing pain relief comparable to morphine, the stock value of MIRA Pharmaceutical ...

Original reporting
Benzinga · Mohd Haider
Published Jul 3, 2025, 5:46 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2025, 6:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours - Mira Pharmaceuticals (NASDAQ:MIRA) — source image
Decision brief

The 30-second read

$MIRABullishHigh
01

Why it matters

The positive clinical data has spurred investor optimism, leading to a 50% after-hours stock jump, indicating strong short-term trading opportunities.

02

Market read

The news is highly relevant for biotech investors and traders focusing on innovative pain relief therapies, with immediate impact on MIRA's stock.

03

What to watch

Potential delays in clinical development, regulatory challenges, or adverse side effects could negate initial enthusiasm.

Timing: short-term (next 1-2 weeks)

Background

MIRA Pharmaceuticals announced promising preclinical results for Mira-55, a synthetic marijuana analog with potent pain-relieving properties comparable to morphine.

Company-level read

Ticker impact

$MIRABullishHigh confidence
Context

High relevance due to recent stock movement and news impact.

Expected impact

Short-term upward momentum expected, with potential for continued gains if clinical results are confirmed and regulatory pathways are favorable.

Evidence & confidence

The immediate stock jump following the news suggests strong investor optimism. The drug's promising preclinical results could translate into value appreciation, especially if subsequent trials are successful.

Market effects

Potential positive impact on biotech and life sciences sectors focusing on cannabinoid-based therapeutics.

Primarily affecting US biotech stocks, with possible ripple effects in related markets.

Limited, as the news pertains to a US-listed biotech company with specific clinical developments.

Counterpoint

The stock surge may be a short-term overreaction; subsequent clinical trial failures or regulatory hurdles could lead to rapid declines.

Key entities

  • MIRA Pharmaceuticals

    Developer of cannabinoid-based therapeutics, focusing on pain management solutions.

Related articles

$MIRAMed

MIRA Flat at Open

MIRA Pharmaceuticals (NASDAQ:MIRA) shares were flat at the open. The company said new preclinical pharmacology data for its cannabinoid analog Mira-55 in chronic inflammatory pain showed a THC-like receptor profile but different effects, including an anxiolytic effect not seen with THC. MIRA also referenced March 2026 animal data versus rimonabant.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.